Subsequent Event Subsequent Event

6 Months Ended

Dec. 28, 2013

Subsequent Event [Line Items]

Subsequent Events [Text Block]

SUBSEQUENT EVENT

As noted in Note 1, the Company had acquired a 14.6% share in Prothena as a result of the Elan acquisition on December 18, 2013. On January 29, 2014, Prothena announced the pricing of an underwritten public offering of 2,767,177 ordinary shares at a price to the public of $26.00 per ordinary share, before underwriting discounts and commissions.  The Company owned all of the ordinary shares sold in the offering. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 415,076 Prothena ordinary shares.  On January 29th, underwriters exercised their option to purchase the additional 415,076 Prothena ordinary shares.  The offering settled on February 3, 2014 for proceeds to the Company, net of underwriting discounts and commissions, of approximately $79.4 million.  As a result of the offering, the Company no longer holds an ownership stake in Prothena. At December 28, 2013, the Company's carrying value in its investment in Prothena was $84.4 million. Between December 18, 2013, the date the Company acquired Elan, and December 28, 2013, the Company recorded an unrealized loss of $4.8 million in OCI related to the change in Prothena's stock price between December 18, 2013 and December 28, 2013. As a result of the offering, the Company expects to recognize a loss on the sale of its investment in Prothena of approximately $9.8 million in the third quarter of fiscal 2014.